Mounjaro (tirzepatide) went from impossible to get in 2023 to widely available in 2026 — but "available" doesn't mean the same thing for every patient. Whether you can actually access it depends on your diagnosis, your insurance, and which route you take.
This guide cuts through the confusion: current supply status, who qualifies for what, cost comparisons, and the telehealth alternatives that have made tirzepatide accessible to patients who couldn't get it through traditional channels.
What Is Mounjaro, and How Does It Differ from Zepbound?
Mounjaro and Zepbound are the same molecule — tirzepatide — made by Eli Lilly. The difference is regulatory and commercial, not clinical:
- Mounjaro (tirzepatide 2.5mg–15mg): FDA-approved for type 2 diabetes management. Covered by many commercial insurance plans for T2D.
- Zepbound (tirzepatide 2.5mg–15mg): FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition. Approved in November 2023.
Both products use the same auto-injector pen and the same dose ladder. The only meaningful practical difference is the indication — and therefore which insurance coverage applies.
Tirzepatide's mechanism is what separates it from older GLP-1s: it activates both GLP-1 and GIP receptors simultaneously (a dual agonist), producing greater average weight loss than semaglutide in head-to-head clinical trials.
Current Availability Status
Brand-Name Supply
The severe shortages of 2023 and early 2024, when patients on Mounjaro routinely encountered empty pharmacy shelves and waitlists, have largely resolved. As of 2026:
- Mounjaro and Zepbound are commercially available at major pharmacy chains and mail-order pharmacies
- Occasional regional shortages of specific dose strengths still occur but are not the norm
- The FDA removed tirzepatide from its drug shortage database in late 2024 after supply stabilized
If you have a valid prescription and can afford the drug (or have coverage), availability is no longer the primary barrier for most patients. Cost is.
Compounded Tirzepatide
When brand-name Mounjaro was in shortage, FDA rules permitted compounding pharmacies to produce tirzepatide as an alternative supply channel. The regulatory situation for compounded tirzepatide has been contested:
- In March 2025, the FDA declared the tirzepatide shortage resolved, which technically ended the compounding permission
- Multiple legal challenges from telehealth companies and compounding pharmacies followed
- The regulatory picture continues to evolve — some platforms still offer compounded tirzepatide; others have paused
Check directly with telehealth platforms for current compounded tirzepatide availability in your state. This is one area where the answer changes month to month.
Who Qualifies for Tirzepatide?
Path 1: Mounjaro for Type 2 Diabetes
To get Mounjaro prescribed:
- Diagnosis of type 2 diabetes (not pre-diabetes, not type 1)
- A provider willing to prescribe (primary care, endocrinologist, or telehealth prescriber)
- Prior authorization may be required by your insurance
Mounjaro is a highly effective diabetes medication in its own right — it reduces HbA1c by an average of 2 percentage points at the highest dose. Patients with T2D who also want weight-loss benefits often pursue Mounjaro specifically because coverage is better than weight-specific options.
Path 2: Zepbound for Obesity / Overweight
To qualify for Zepbound:
- BMI ≥30, or
- BMI ≥27 plus at least one weight-related condition: hypertension, dyslipidemia, type 2 diabetes, sleep apnea, or cardiovascular disease
- A licensed provider assessment
Commercial insurance coverage for Zepbound has been inconsistent — many plans exclude weight-loss medications entirely. Federal employees gained Zepbound coverage in 2025 under a rule change. Most patients pay out of pocket or use manufacturer savings cards.
Path 3: Telehealth with Compounded or Brand Tirzepatide
Telehealth platforms have created a third access route:
- Online consultation with a licensed provider (typically 15–30 minutes)
- Provider evaluates weight history, BMI, comorbidities, and medication history
- If clinically appropriate, prescribes Zepbound or compounded tirzepatide
- Medication ships to your door from affiliated pharmacy
This path doesn't require an in-person visit, prior authorization navigation, or insurance. It does require out-of-pocket payment — but prices through telehealth are often significantly lower than retail brand-name pricing.
Cost Comparison: All Your Options
| Access Route | Medication | Monthly Cost | Notes |
|---|---|---|---|
| Commercial pharmacy (brand) | Mounjaro | ~$1,000–$1,100 | Without insurance |
| Commercial pharmacy (brand) | Zepbound | ~$1,000–$1,100 | Without insurance |
| Lilly Savings Card | Mounjaro/Zepbound | $25–$550 | Commercially insured only; eligibility requirements apply |
| Insurance (T2D) | Mounjaro | Varies (often $50–$200 copay) | Requires T2D diagnosis; prior auth common |
| Telehealth (compounded) | Tirzepatide | $150–$450 | Availability varies; regulatory situation evolving |
| Telehealth (brand Zepbound) | Zepbound | $350–$600 | Some platforms ship brand at wholesale pricing |
Prices reflect 2026 market data. Verify directly with platforms and pharmacies for current pricing.
Telehealth Providers That Offer Tirzepatide
Several GLP-1 telehealth platforms have built tirzepatide prescribing into their programs. Key considerations when comparing:
| Provider | Tirzepatide Availability | Price Range | Notes |
|---|---|---|---|
| Hims & Hers | Compounded + brand | $150–$399/mo | Compounded availability varies by state |
| Ro Body | Brand Zepbound | $350–$600/mo | Focus on brand medication access |
| LifeMD | Brand + compounded | $200–$450/mo | Includes medical provider support |
| Noom Med | Brand Zepbound | Varies | Combined behavioral + medication program |
| Form Health | Brand | Provider-dependent | Higher-touch clinical model |
This table reflects general program structures. Specific pricing, state availability, and compounding policies change frequently. Use our provider comparison tool for real-time data.
The right choice depends on whether you want compounded tirzepatide (lower cost, regulatory uncertainty) or brand Zepbound (more stability, higher cost), and which platforms operate in your state.
How Mounjaro Compares to Semaglutide Alternatives
If tirzepatide isn't accessible or affordable for you, semaglutide-based medications (Ozempic, Wegovy, compounded semaglutide) are the next option. Key differences:
On efficacy: Tirzepatide produces more weight loss on average — roughly 20% of body weight in SURMOUNT-5 vs. 13.7% for semaglutide at maximum doses. But semaglutide still produces clinically meaningful weight loss, and individual responses vary.
On cost: Compounded semaglutide is more widely available and typically cheaper ($99–$299/month through many platforms) than compounded tirzepatide.
On supply: Brand semaglutide (Wegovy, Ozempic) has had its own shortage history; compounded semaglutide availability has also faced regulatory pressure. Both drug classes require due diligence on current access.
For a deeper comparison, see our tirzepatide vs. semaglutide guide.
What to Expect at a Telehealth Consultation
If you decide to pursue tirzepatide through a telehealth platform, here's the typical process:
- Intake form: Medical history, weight history, medications, allergies. Usually completed before the visit.
- Provider consultation: Video or asynchronous message review. The provider confirms eligibility, discusses goals, and explains the titration schedule.
- Prescription and pharmacy coordination: The platform sends the prescription to their affiliated pharmacy, which ships directly to you.
- Ongoing check-ins: Most platforms require periodic check-ins to monitor progress and adjust dosing. Frequency varies by provider.
Starting dose is always 2.5mg/week. The standard titration ladder increases by 2.5mg every 4 weeks, up to 15mg/week for patients who tolerate escalation and need additional effect.
The Bottom Line
Mounjaro availability has improved dramatically since the shortage years — but accessing it at an affordable price still requires strategy. For most patients paying out of pocket:
- Telehealth is the primary access route for tirzepatide at non-brand prices
- Zepbound or compounded tirzepatide are the practical options depending on your state and the current regulatory status of compounding
- Insurance coverage is meaningful if you have T2D (Mounjaro) or are among the growing group of commercial and federal insurance plans covering Zepbound
The landscape changes faster than most articles can keep up with. Use current comparison tools — not cached information — when making your access decision.
Want to see which platforms currently prescribe tirzepatide in your state? Use our provider comparison tool to get matched based on your location, diagnosis, and budget.
This article is for informational purposes only and does not constitute medical advice. Tirzepatide requires a prescription from a licensed healthcare provider. Discuss your eligibility and options with a qualified clinician.